K

Kilitch Drugs (India) Ltd
NSE:KILITCH

Watchlist Manager
Kilitch Drugs (India) Ltd
NSE:KILITCH
Watchlist
Price: 336.8 INR -5.41% Market Closed
Market Cap: 5.4B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one KILITCH stock under the Base Case scenario is 282.65 INR. Compared to the current market price of 336.8 INR, Kilitch Drugs (India) Ltd is Overvalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KILITCH Relative Value
Base Case
282.65 INR
Overvaluation 16%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

3
P/S
P/S
Price to Sales
3
vs History
38
vs Industry
36
Median 3Y
2.7
Median 5Y
2.7
Industry
2.4
Forward
2.4
More Details
27.8
P/E
P/E
Price to Earnings
27.8
vs History
76
vs Industry
15
Median 3Y
30.9
Median 5Y
37.2
Industry
20.5
Forward
27.8
More Details
25.8
P/OCF
P/OCF
Price to OCF
25.8
vs History
31
vs Industry
15
Median 3Y
24
Median 5Y
9.5
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
3
Median 3Y
-21.7
Median 5Y
-25.2
Industry
22.8
More Details
2.9
P/B
P/B
Price to Book Value
2.9
vs History
20
vs Industry
24
Median 3Y
2.4
Median 5Y
2
Industry
1.9
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
31
vs Industry
37
Median 3Y
2.5
Median 5Y
2.4
Industry
2.5
Forward
2.3
More Details
8.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.3
vs History
26
vs Industry
23
Median 3Y
6.7
Median 5Y
6.5
Industry
4.9
More Details
21.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
21.9
vs History
44
vs Industry
16
Median 3Y
20.7
Median 5Y
21.1
Industry
12.4
Forward
13.7
More Details
25.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
25.3
vs History
49
vs Industry
16
Median 3Y
24
Median 5Y
25.3
Industry
15.5
Forward
15.3
More Details
24.5
EV/OCF
EV/OCF
Enterprise Value to OCF
24.5
vs History
31
vs Industry
16
Median 3Y
22.8
Median 5Y
7.9
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
3
Median 3Y
-87.2
Median 5Y
-90.2
Industry
17.9
More Details
3
EV/IC
EV/IC
Enterprise Value to IC
3
vs History
22
vs Industry
23
Median 3Y
2.5
Median 5Y
2.1
Industry
1.8
More Details

Multiples Across Competitors

KILITCH Competitors Multiples
Kilitch Drugs (India) Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Kilitch Drugs (India) Ltd
NSE:KILITCH
5.4B INR 3 27.8 21.9 25.3
US
Eli Lilly and Co
NYSE:LLY
699.5B USD 15.5 66.1 38.5 42.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
368.8B USD 4.2 26.2 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.4 12.1 13.8
CH
Roche Holding AG
SIX:ROG
196.6B CHF 3.3 17.1 9.7 11.5
CH
Novartis AG
SIX:NOVN
177.2B CHF 4 17.4 10.6 13.5
UK
AstraZeneca PLC
LSE:AZN
159.2B GBP 3.8 29.2 125.7 192
US
Merck & Co Inc
NYSE:MRK
206.3B USD 3.2 12.1 8.2 9.7
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
115.9B EUR 2.6 20.2 8.8 12.9
P/E Multiple
Earnings Growth PEG
IN
K
Kilitch Drugs (India) Ltd
NSE:KILITCH
Average P/E: 26
27.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.2
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.4
19%
1
CH
Roche Holding AG
SIX:ROG
17.1
16%
1.1
CH
Novartis AG
SIX:NOVN
17.4
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
20.2
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
K
Kilitch Drugs (India) Ltd
NSE:KILITCH
Average EV/EBITDA: 395.8
21.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.5
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.7
8%
1.2
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
125.7
9%
14
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.8
7%
1.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
K
Kilitch Drugs (India) Ltd
NSE:KILITCH
Average EV/EBIT: 1 699.1
25.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.5
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
9%
1.3
CH
Novartis AG
SIX:NOVN
13.5
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
192
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.9
14%
0.9

See Also

Summary
KILITCH intrinsic value, competitors valuation, and company profile.
DCF Valuation
KILITCH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KILITCH stock valuation using valuation multiples.
Wall Street Estimates
KILITCH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KILITCH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 244,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.